Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Novartis AG stock logo
NVS
Novartis
$154.61
-1.4%		$153.21
$118.34
▼
$170.46
$295.02B0.451.96 million shs1.07 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Novartis AG stock logo
NVS
Novartis
+0.27%+2.01%+1.78%+5.80%+34.25%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Novartis AG stock logo
NVS
Novartis
$154.61
-1.4%		$153.21
$118.34
▼
$170.46
$295.02B0.451.96 million shs1.07 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Novartis AG stock logo
NVS
Novartis
+0.27%+2.01%+1.78%+5.80%+34.25%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Novartis AG stock logo
NVS
Novartis
2.31
Hold$141.20-8.68% Downside

Current Analyst Ratings Breakdown

Latest NVS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/24/2026
Novartis AG stock logo
NVS
Novartis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy (B)
7/22/2026
Novartis AG stock logo
NVS
Novartis
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
(Data available from 8/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Novartis AG stock logo
NVS
Novartis
$54.53B5.41$10.62 per share14.56$22.04 per share7.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Novartis AG stock logo
NVS
Novartis
$13.98B$6.6323.3215.762.6723.29%38.56%14.47%10/27/2026 (Estimated)

Latest NVS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/21/2026Q2 2026
Novartis AG stock logo
NVS
Novartis
$2.17$2.41+$0.24$1.71$14.07 billion$14.41 billion
6/30/2026Q2 2026
Novartis AG stock logo
NVS
Novartis
N/A$2.41N/A$1.71N/A$14.95 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Novartis AG stock logo
NVS
Novartis
$3.081.99%+5.28%46.46%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Novartis AG stock logo
NVS
Novartis
0.89
0.86
0.67

Institutional Ownership

CompanyInstitutional Ownership
Novartis AG stock logo
NVS
Novartis
13.12%

Insider Ownership

CompanyInsider Ownership
Novartis AG stock logo
NVS
Novartis
0.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Novartis AG stock logo
NVS
Novartis
75,2671.91 billion1.91 billionOptionable

Recent News About These Companies

Erste Group Bank Forecasts Weaker Earnings for Novartis
August 11 at 8:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/erste-group-bank-forecasts-weaker-earnings-for-novartis-2026-08-11/
Novartis AG Sponsored ADR
August 9 at 8:47 AM  |  cnn.comhttps://www.cnn.com/markets/stocks/NVS
Zacks Research Comments on Novartis' Q3 Earnings (NYSE:NVS)
August 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30945193
The Manufacturers Life Insurance Company Sells 24,216 Shares of Novartis AG $NVS
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-the-manufacturers-life-insurance-company-sells-24216-shares-of-novartis-ag-nvs-2026-08-06/
Research Analysts Offer Predictions for Novartis Q3 Earnings
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/research-analysts-offer-predictions-for-novartis-q3-earnings-2026-08-05/
Segall Bryant & Hamill LLC Purchases Shares of 18,792 Novartis AG $NVS
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-segall-bryant-hamill-llc-purchases-shares-of-18792-novartis-ag-nvs-2026-08-05/
Glenmede Trust Co. NA Acquires 8,680 Shares of Novartis AG $NVS
August 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-glenmede-trust-co-na-acquires-8680-shares-of-novartis-ag-nvs-2026-08-04/
FDA approval nearly doubles eligible patient pool for Novartis' Pluvicto
August 3, 2026  |  msn.comhttps://www.msn.com/en-us/health/general/fda-approval-nearly-doubles-eligible-patient-pool-for-novartis-pluvicto/ar-AA29jTUP
Novartis AG $NVS Shares Sold by Public Employees Retirement System of Ohio
August 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-novartis-ag-nvs-shares-sold-by-public-employees-retirement-system-of-ohio-2026-08-03/
Henshaw Capital LLC Grows Stock Position in Novartis AG $NVS
August 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-henshaw-capital-llc-grows-stock-position-in-novartis-ag-nvs-2026-08-02/
FY2026 EPS Estimates for Novartis Raised by Erste Group Bank
August 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30935315
Novartis AG $NVS Shares Purchased by Royal Bank of Canada
August 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-novartis-ag-nvs-shares-purchased-by-royal-bank-of-canada-2026-08-01/
Bank of America Corp DE Raises Stock Holdings in Novartis AG $NVS
August 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-raises-stock-holdings-in-novartis-ag-nvs-2026-08-01/
Erste Group Bank Forecasts Increased Earnings for Novartis
July 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/erste-group-bank-forecasts-increased-earnings-for-novartis-2026-07-31/
Novartis AG $NVS Shares Bought by Janus Henderson Group PLC
July 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-novartis-ag-nvs-shares-bought-by-janus-henderson-group-plc-2026-07-31/
Novartis AG $NVS Shares Bought by Empowered Funds LLC
July 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-novartis-ag-nvs-shares-bought-by-empowered-funds-llc-2026-07-31/
Arrowstreet Capital Limited Partnership Sells 679,380 Shares of Novartis AG $NVS
July 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-arrowstreet-capital-limited-partnership-sells-679380-shares-of-novartis-ag-nvs-2026-07-31/
Analysts Offer Insights on Healthcare Companies: Novartis (NVS) and NeoGenomics (NEO)
July 30, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NVS-N/pressreleases/3547501/analysts-offer-insights-on-healthcare-companies-novartis-nvs-and-neogenomics-neo/
Quantinno Capital Management LP Acquires 39,537 Shares of Novartis AG $NVS
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-quantinno-capital-management-lp-acquires-39537-shares-of-novartis-ag-nvs-2026-07-30/
Ashton Thomas Securities LLC Makes New Investment in Novartis AG $NVS
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-ashton-thomas-securities-llc-makes-new-investment-in-novartis-ag-nvs-2026-07-30/
Novartis chart may soon 'complete a well-defined bullish reversal,' Cappelleri says
July 29, 2026  |  cnbc.comhttps://www.cnbc.com/2026/07/29/novartis-chart-may-soon-complete-a-well-defined-bullish-reversal.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Novartis stock logo

Novartis NYSE:NVS

$154.61 -2.18 (-1.39%)
Closing price 03:59 PM Eastern
Extended Trading
$154.62 +0.00 (+0.00%)
As of 06:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas